The Patent Finder

Advanced Accelerator Applications SA

21 patents currently held · Updated Nov 18, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

7
Ending by 2030
Aug 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 9, 2026
    The maintenance fee for Sultone compound derivatives substituted by nucleophiles, in particular radionuclides, and use thereof for marking macromolecules (US 9,051,292) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
  • 1 fee due Aug 20, 2027
    The maintenance fee for Stable, concentrated radionuclide complex solutions (US 11,904,027) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
  • 2 fees due Sep 24, 2027

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,268,594pyrC as a selection marker in Escherichia coli
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,388,972Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,741,850Compounds modulators of VEGF activity and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,737,622Compounds modulators of VEGF activity and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,546,526Selective Alfavbeta3 Receptor Peptide Antagonist for Therapeutic and Diagnostic Applications
In force
 · High confidence
In forceHigh confidence
US 9,017,938Use of MICRORNA-199B-5P in Medical and Diagnostic Field
In force
 · High confidence
In forceHigh confidence
US 9,051,292Sultone compound derivatives substituted by nucleophiles, in particular radionuclides, and use thereof for marking macromolecules
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,839,703Radiolabeled Grpr-Antagonists for Diagnostic Imaging and Treatment of Grpr-Positive Cancer
In force
 · High confidence
In forceHigh confidence
US 9,611,215Nucleophile-reactive sulfonated compounds for the (radio)labelling of (bio) molecules; precursors and conjugates thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,196,421Nucleophile-reactive sulfonated compounds for the (radio)labelling of (bio)molecules; precursors and conjugates thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 21 patents shown.
Pro members see all 21.
Pro members: see all 21 patents
Also on record, not counted in the 21: 2 patents in force now held by others · 1 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 3 abandoned · 3 no status recorded

Showing 1 to 8 of 8, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/231,931Stable, concentrated radionuclide complex solutionsJun 9, 2025Pending
19/084,265Stable, concentrated radionuclide complex solutionsMar 19, 2025Pending
18/927,034Stable, concentrated radionuclide complex solutionsOct 25, 2024Abandoned
18/597,037Method of Treatment of Neuroendocrine TumorsMar 6, 2024Abandoned
17/209,122Mar 22, 2021No status recorded
17/209,121Mar 22, 2021No status recorded
17/263,140Method of Treatment of Neuroendocrine TumorsJul 24, 2019Abandoned
16/229,109Dec 21, 2018No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited